NU51CK000376
Cooperative Agreement
Overview
Grant Description
Utah's proposal for activities within the 2024 Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC) Cooperative Agreement.
A. Cross-cutting EPI and lab capacity: Assessments and training; enhance skills; build support and capacity; improve disease dashboards; conduct appropriate testing; improve efficiency; improve data quality; automate data export and analysis; collaborate with partners; lab landscape analysis.
B. ELC leadership, management, and administration: Plan and coordinate activities; manage financial aspects; improve outcomes; report on progress.
C. Health information systems capacity: Improve functionality; sustainability plan; evaluate data; address gaps; simplify review of data quality and compliance; identify best practices; improve data quality; collaborate for and streamline onboarding; modernize pipelines and reporting; support modernized infrastructure; migrate systems to cloud-based/hosted environments; implement scalable data management.
D. Advanced molecular detection: AMD regional workforce development training lead; develop AMD bioinformatics resources.
E. National wastewater surveillance system: Data coordination, submission, timeliness, and quality; disseminate data; expand lab capacity; automate data transfer; coordinate and communicate data.
F. Cross-cutting emerging issues: Coordinate with CDC if funded.
G. Enteric, foodborne, waterborne, and zoonotic diseases: Improve interview timeliness and lab coordination; training; use data to identify prevention opportunities; implement model practices; translate materials; begin collaboration on public dashboard; participate in strategic planning; enhance surveillance; create guidance for specimens; improve communication; promote awareness; build partnerships; improve metagenomics methods.
H. Healthcare-associated infections, antimicrobial resistance, and antibiotic stewardship: Implement responses; support case and outbreak investigations; prevent spread of MDROs; conduct on-site infection prevention and control assessments; address health disparities; improve antibiotic stewardship capacity; update SOPs; provide IPC training.
I. Antimicrobial resistance laboratory network: Maintain trained staff; monitor compliance; conduct sequencing; train and monitor competency; sustain and establish lab capacity; surveillance on specific organisms; colonization screening testing; support EPI investigations; maintain AR lab expert; provide outreach, develop protocols; maintain and sustain reporting.
J. Enhanced surveillance for vaccine-preventable disease and respiratory diseases: Maintain staff; collect case data; increase reporting; outbreak investigations; improve surveillance; support testing capacity; linkage of data; coordinate activities.
K. Vector-borne diseases and tick-associated conditions: Identify and report cases and blood donations; MMG onboarding; collect and report passive data; provide guidance; conduct pathogen testing; analyze and interpret data; maintain and enhance testing capacity; proficiency testing; outreach.
L. Prion surveillance: Identify and investigate cases; use surveillance; support evidence-based and cost-effective policies; work collaboratively with partners; identify autopsy facilities; conduct outreach; disseminate information on prion disease; provide education.
M. Mycotics. Detecting and preventing fungal infections: Use case definitions; conduct enhanced surveillance; report outbreaks; collaborate with CDC; participate in fungal outbreak investigations; establish fungal testing capacity; lab personnel training; disseminate materials and information; maintain partnerships; identify and implement interventions.
R. Rabies surveillance and laboratory capacity: Sample collection and testing.
S. Surveillance for emerging threats to pregnant people and infants network: Develop case ascertainment plan; develop data linkages; conduct case ascertainment and follow-up; specify data elements; modernize core surveillance capacity; work with partners; perform outreach; analyze and prepare data; specify new processes.
A. Cross-cutting EPI and lab capacity: Assessments and training; enhance skills; build support and capacity; improve disease dashboards; conduct appropriate testing; improve efficiency; improve data quality; automate data export and analysis; collaborate with partners; lab landscape analysis.
B. ELC leadership, management, and administration: Plan and coordinate activities; manage financial aspects; improve outcomes; report on progress.
C. Health information systems capacity: Improve functionality; sustainability plan; evaluate data; address gaps; simplify review of data quality and compliance; identify best practices; improve data quality; collaborate for and streamline onboarding; modernize pipelines and reporting; support modernized infrastructure; migrate systems to cloud-based/hosted environments; implement scalable data management.
D. Advanced molecular detection: AMD regional workforce development training lead; develop AMD bioinformatics resources.
E. National wastewater surveillance system: Data coordination, submission, timeliness, and quality; disseminate data; expand lab capacity; automate data transfer; coordinate and communicate data.
F. Cross-cutting emerging issues: Coordinate with CDC if funded.
G. Enteric, foodborne, waterborne, and zoonotic diseases: Improve interview timeliness and lab coordination; training; use data to identify prevention opportunities; implement model practices; translate materials; begin collaboration on public dashboard; participate in strategic planning; enhance surveillance; create guidance for specimens; improve communication; promote awareness; build partnerships; improve metagenomics methods.
H. Healthcare-associated infections, antimicrobial resistance, and antibiotic stewardship: Implement responses; support case and outbreak investigations; prevent spread of MDROs; conduct on-site infection prevention and control assessments; address health disparities; improve antibiotic stewardship capacity; update SOPs; provide IPC training.
I. Antimicrobial resistance laboratory network: Maintain trained staff; monitor compliance; conduct sequencing; train and monitor competency; sustain and establish lab capacity; surveillance on specific organisms; colonization screening testing; support EPI investigations; maintain AR lab expert; provide outreach, develop protocols; maintain and sustain reporting.
J. Enhanced surveillance for vaccine-preventable disease and respiratory diseases: Maintain staff; collect case data; increase reporting; outbreak investigations; improve surveillance; support testing capacity; linkage of data; coordinate activities.
K. Vector-borne diseases and tick-associated conditions: Identify and report cases and blood donations; MMG onboarding; collect and report passive data; provide guidance; conduct pathogen testing; analyze and interpret data; maintain and enhance testing capacity; proficiency testing; outreach.
L. Prion surveillance: Identify and investigate cases; use surveillance; support evidence-based and cost-effective policies; work collaboratively with partners; identify autopsy facilities; conduct outreach; disseminate information on prion disease; provide education.
M. Mycotics. Detecting and preventing fungal infections: Use case definitions; conduct enhanced surveillance; report outbreaks; collaborate with CDC; participate in fungal outbreak investigations; establish fungal testing capacity; lab personnel training; disseminate materials and information; maintain partnerships; identify and implement interventions.
R. Rabies surveillance and laboratory capacity: Sample collection and testing.
S. Surveillance for emerging threats to pregnant people and infants network: Develop case ascertainment plan; develop data linkages; conduct case ascertainment and follow-up; specify data elements; modernize core surveillance capacity; work with partners; perform outreach; analyze and prepare data; specify new processes.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding Agency
Place of Performance
Utah
United States
Geographic Scope
State-Wide
Related Opportunity
Analysis Notes
Amendment Since initial award the End Date has been shortened from 07/31/29 to 07/31/26 and the total obligations have increased 6892% from $203,761 to $14,246,583.
Utah Department Of Health And Human Services was awarded
Utah ELC Proposal: Enhancing Disease Surveillance & Response
Cooperative Agreement NU51CK000376
worth $14,246,583
from National Center for Emerging and Zoonotic Infectious Diseases in August 2024 with work to be completed primarily in Utah United States.
The grant
has a duration of 2 years and
was awarded through assistance program 93.323 Epidemiology and Laboratory Capacity for Infectious Diseases (ELC).
The Cooperative Agreement was awarded through grant opportunity Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC).
Status
(Ongoing)
Last Modified 9/24/25
Period of Performance
8/1/24
Start Date
7/31/26
End Date
Funding Split
$14.2M
Federal Obligation
$0.0
Non-Federal Obligation
$14.2M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for NU51CK000376
Transaction History
Modifications to NU51CK000376
Additional Detail
Award ID FAIN
NU51CK000376
SAI Number
NU51CK000376-819753582
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
State Government
Awarding Office
75CDC1 CDC Office of Financial Resources
Funding Office
75CVL0 CDC NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES
Awardee UEI
C172TQML5G99
Awardee CAGE
3LRJ4
Performance District
UT-90
Senators
Mike Lee
Mitt Romney
Mitt Romney
Modified: 9/24/25